Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Blood Cells, Molecules & Diseases|October 26, 2005
Increased incidence of cancer in adult Gaucher disease in Western EuropeM de Fost, S Vom Dahl, G J Weverling, et al.
Placenta|March 2, 2010
Analysis of placental tissue in Fabry disease with and without enzyme replacement therapyM G Bouwman, C E M Hollak, M A van den Bergh Weerman, et al.
Biochimica Et Biophysica Acta|December 25, 2007
Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic interventionJ E M Groener, B J H M Poorthuis, S Kuiper, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 18, 2005
Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseasesJ M F G Aerts, C E M Hollak, M van Breemen, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|May 31, 2022
A vitamin a day keeps the doctor away: The need for high quality pyridoxal-5'-phosphateN N Stolwijk, M M Brands, L S Smit, et al.
Molecular Genetics and Metabolism|November 11, 2009
Vasculopathy in patients with Fabry disease: current controversies and research directionsS M Rombach, Th B Twickler, J M F G Aerts, et al.
Journal of Inherited Metabolic Disease|April 8, 2006
Manifestations of Fabry disease in placental tissueA C Vedder, A Strijland, M A vd Bergh Weerman, et al.
Molecular Genetics and Metabolism|November 27, 2018
Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatmentS J van der Veen, A B P van Kuilenburg, C E M Hollak, et al.
Journal of Inherited Metabolic Disease|May 17, 2014
Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapyL van Dussen, E J Hendriks, J E M Groener, et al.
European Journal of Clinical Pharmacology|June 9, 2026
From authorisation to clinical practice: evolution of the use of biological medicines according to the SmPC and guidelines (2006 to 2025)B M F Penninx, C E M Hollak, S W Tas, et al.
Pageof 6